PMC8542851_01
(A) The blood cell and PCM1-JAK2 fusion transcript changes in patient 1 over the course of the disease. (B) The blood cell changes in patient 2 over the course of the disease. WBC, white blood cells; HB, hemoglobin; PLT, platelet; Eo, eosinophils.
fonc-11-753842-g001.jpg
PMC8542851_02_fonc-11-753842-g001.jpg
f1
In short, the patient cannot tolerate the therapeutic dose of ruxolitinib and is preparing for allo-HSCT ( Figure 1B ).
PMC8542851_02
(A) The blood cell and PCM1-JAK2 fusion transcript changes in patient 1 over the course of the disease. (B) The blood cell changes in patient 2 over the course of the disease. WBC, white blood cells; HB, hemoglobin; PLT, platelet; Eo, eosinophils.
fonc-11-753842-g001.jpg
PMC8542851_02_fonc-11-753842-g001.jpg
f1
In short, the patient cannot tolerate the therapeutic dose of ruxolitinib and is preparing for allo-HSCT ( Figure 1B ).